

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

41317

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/744176

INTERNATIONAL APPLICATION NO.
PCT/EP99/05173

INTERNATIONAL FILING DATE
20 July 1999

PRIORITY DATE CLAIMED
21 July 1998

TITLE OF INVENTION
ANTI HEPATITIS C VIRUS ANTIBODY AND USES THEREOF

APPLICANT(S) FOR DO/EO/US
Christian Reiter et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Written Opinion

First Page of the Published Application

Notification of the Recording of a Change

International Search Report

Request

Article 34 Amendment

EP99/00161

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO **\$970.00**

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO..... **\$840.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$690.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$670.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) **\$96.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS** PTO USE ONLY

\$ 840.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	24 - 20 =	4	X \$18.00
Independent claims	2 - 3 =		X \$78.00

\$ 72.00

\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable)

+ \$260.00

\$ 260.00

TOTAL OF ABOVE CALCULATIONS =

\$ 1172.00

Reduction of 1/2 for filing by small entity, if applicable. Small Entity Status applies

\$ 586.00

SUBTOTAL =

\$ 586.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

+

TOTAL NATIONAL FEE =

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property

+

\$

TOTAL FEES ENCLOSED =

\$ 586.00

Amount to be
refunded:

\$

charged:

\$

a. ☒ A check in the amount of \$ 586.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 18-2220. A duplicate copy of this sheet is enclosed.

The Declaration/Power of Attorney and Assignment will be filed shortly.

Priority is claimed from DE 98 113595.7 filed 21 July 1998.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Roylance, Abrams, Berdo & Goodman, L.L.P.

1300 19th Street, N.W., Suite 600

Washington, D.C. 20036

(202) 659-9076

SIGNATURE:

Dean H. Nakamura

NAME

33,981

REGISTRATION NUMBER

New PCT Application
Our Ref.: B 3070 PCT

7/PRTJ

09/744176

JC07 Rec'd PET/PTO 19 JAN 2001
VOSSIUS & PARTNER
PATENTANWÄLTE
SIEBERTSTR. 4
81675 MÜNCHEN

20. Juli 1999

TITLE OF THE INVENTION

Anti Hepatitis C virus antibody and uses thereof

FIELD OF THE INVENTION

The present invention concerns human antibodies capable of specifically binding to conformation-dependent epitopes of Hepatitis C virus (HCV) glycoprotein E2 and various uses thereof.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

BACKGROUND OF THE INVENTION

Hepatitis C virus (HCV) is the principal causative agent for non-A, non-B Hepatitis. The prevalence of HCV infection in the blood donor population has been estimated to range from 0.4 to 2% (Choo et al., 1989). Acute HCV infection leads, in more than 70% of the patients, to the development of chronic hepatitis that can evolve towards cirrhosis and hepatocellular carcinoma (Saito et al., 1990). HCV is an enveloped positive-stranded RNA virus which is classified in the Flaviviridae family (Francki et al., 1991, Miller et al., 1990). It contains a genome of about 9,500 nts encoding a polyprotein of 3010 to 3033 amino acids. Processing of the polyprotein by host and viral proteases results in the production of structural and nonstructural (NS) proteins (Rice et al., 1996). Structural proteins include a nucleocapsid and two putative virion

envelope glycoproteins E1 and E2 (Miyamura et al., 1993). Non-structural proteins include NS2 to NS5 antigens.

In some individuals, acute infection successfully resolves indicating that HCV can be controlled by the host immune system. The mechanisms by which the host overcomes HCV infection remain unknown. Previous reports strongly suggest that humans and chimpanzees can generate virus-neutralizing antibodies (Choo et al., 1994, Farci et al., 1994, 1996, Shimizu et al., 1994). Successful *in vivo* protection of chimpanzees from primary infection by an homologous HCV isolate has been achieved following immunization with recombinant E1 and E2 proteins (Choo et al., 1994). In that study only those chimpanzees showing high anti-E2 antibody titers were protected. While neutralizing antigenic domains were not identified, it was postulated that conformation of the immunogens was critical for the induction of neutralizing antibodies.

As there is to date no efficient *in vitro* replication system to grow the virus and develop neutralization assays, alternative assays to assess the biological function of anti-E1/E2 antibodies are actively searched for. Prevention of viral attachment onto presumed susceptible cells has been described in preliminary studies (Shimizu et al., 1994, Zibert et al., 1995). More recently, an "in vitro" neutralization of binding (NOB) assay has been developed that is exploiting the specific binding of a highly purified E2 protein onto susceptible target cells (Rosa et al., 1996). This assay allows the quantitative evaluation of NOB antibodies that are capable of neutralizing the binding of E2 onto such cells. Using this system, Rosa et al., have shown that only those chimpanzees immunized with E1 and E2 proteins that developed high anti-NOB titers were protected against challenged infection (Rosa et al., 1996), suggesting that NOB activity could be an indication for "in vivo" neutralization of viral infection. In HIV infection, a similar model has recently shown that affinity of antibody binding to envelope glycoprotein oligomers was a good predictor for virus neutralization (Fouts et al., 1997). Another way to assess the biological activity of anti-E1 and/ or anti-E2 antibodies consists in testing the ability of such antibodies to recognize native structures believed to exist on the surface of virions. *In vitro* studies have shown that E1 and E2 interact to form non-covalently linked complexes (Deleersnyder et al.,

1997, Ralston et al., 1993). Such complexes have been proposed to represent functional subunits of HCV virions (Deleersnyder et al., 1997, Dubuisson et al., 1994, Dubuisson and Rice, 1996, Ralston et al., 1993). Probing for the B-cell repertoire in viral infections is critical for the understanding of pathogenesis associated with these infections. Human monoclonal antibodies provide an alternative method to do so. Isolation and characterization of such antibodies have been reported in the case of HCV for only a limited number of viral antigens. These include the nucleocapsid, the NS3 and NS4 proteins (Akatsuka et al., 1993, Cerino et al., 1991, 1993, Chan et al., 1996, Mondelli et al., 1994) and more recently the glycoprotein E2 (Chan et al., 1996). In this latter case, authors used the phage display technology coupled with the use of synthetic peptides for the screening of the anti-E2 immune reactivity and were able to obtain specific IgG single-chain Fvs that recognized the E2 sequence. While a specific linear epitope sequence was identified, no biological activity for the anti-E2 antibody was described and the putative role of this antibody in the control or progression of infection remains undefined. Recently, WO97/40176 described immunoglobulin molecules obtained from a combinatorial library, which are capable of specifically binding with HCV E2 antigen. Although Fab-fragments of such immunoglobulins were demonstrated to have binding activity in a neutralization of binding assay recombinantly expressed Fab clones and corresponding whole IgG molecules were found to be negative in neutralizing the binding of the HCV E2 polypeptide.

SUMMARY OF THE INVENTION

The present invention relates to novel antibodies comprising at least one complementarity determining region (CDR) of the variable domain of a human antibody which is capable of specifically recognizing a conformation dependent epitope of HCV glycoprotein E2. Furthermore, the present invention relates to antigens recognized by said antibodies. In addition, the present invention relates to a polynucleotide encoding the above-described antibody or antigen, vectors comprising said polynucleotide as well as cells comprising the afore-mentioned

polynucleotide or vector. A further aspect of the invention is a method for preparing antibodies capable of recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of the E2 protein onto susceptible cells. The present invention further involves pharmaceutical and diagnostic compositions comprising the afore-mentioned antibodies, antigens, polynucleotides, vectors or cells as well as the use of the afore-described compounds in various therapeutic and diagnostic applications.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

Accordingly, the technical problem of the invention is to provide means and methods for the treatment and prevention of HCV infection in humans.

The solution to this technical problem is achieved by providing the embodiments characterized in the claims, namely antibodies are provided that 1) recognize conformation-dependent determinant(s), 2) were capable of recognizing antigens derived from different HCV genotypes and 3) were able to precipitate noncovalently associated E1E2 complexes believed to exist on the surface of virion particles; and 4) are capable of neutralizing the binding of E2 protein onto susceptible cells suggesting the potential of the antibodies for in vivo neutralization. Such antibodies are particularly useful for the development of therapeutic or preventive strategies to fight infection by a highly mutable agent such as HCV.

Accordingly, the invention relates to an antibody comprising at least one (preferably two, more preferably three, four or five, and most preferably six) complementarity determining region (CDR) of the V_H and/or V_L region of a human antibody comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 5 (V_L) (SEQ ID NO: 1) and Figure 6 (V_H) (SEQ ID NO: 3) that specifically recognizes a conformation-dependent epitope of Hepatitis C Virus glycoprotein E2 and is capable of precipitating covalently or non-covalently associated E2/E1 complexes. Alternatively, and/or in addition the antibody of the invention comprises at least 1, 2 or 3 CDR(s) of the V_L region of a human immunoglobulin chain comprising the amino

acid sequence of SEQ ID NO: 6 and encoded by the DNA sequence depicted in SEQ ID NO: 5 which represents an allelic variant of the V_L encoding DNA sequence of SEQ ID NO: 1 (Figure 5).

The person skilled in the art knew that each variable domain (the heavy chain V_H and light chain V_L) of an antibody comprises three hypervariable regions, sometimes called complementarity determining regions or "CDRs" flanked by four relatively conserved framework regions or "FRs". The CDRs contained in the variable regions of the antibody of the invention can be determined, e.g., according to Kabat, Sequences of Proteins of Immunological Interest (U.S. Department of Health and Human Services, third edition, 1983, fourth edition, 1987, fifth edition 1990). The person skilled in the art will readily appreciate that the variable domain of the antibody having the above-described variable domain can be used for the construction of other polypeptides or antibodies of desired specificity and biological function. Thus, the present invention also encompasses polypeptides and antibodies comprising at least one CDR of the above-described variable domain and which advantageously has substantially the same or similar binding properties as the antibody described in the appended examples. The person skilled in the art will readily appreciate that using the variable domains or CDRs described above antibodies can be constructed according to methods known in the art, e.g., as described in EP-A1 0 451 216 and EP-A1 0 549 581.

The term "conformation-dependent epitope of Hepatitis C Virus glycoprotein E2" denotes the non-linear nature of the epitope recognized by the antibody of the invention. This means that the antigen's determinants of the epitope are provided by the three-dimensional structure of the HCV glycoprotein E2 rather than by the amino acid sequence as such.

The term "capable of precipitating covalently or non-covalently associated E2/E1 complexes" refers to the ability of the antibody of the invention to precipitate E1 and E2 noncovalently associated complexes which are believed to exist on the virion particle.

The term "capable of neutralizing the binding of E2 protein onto susceptible cells" describes the ability of candidate antibodies to neutralize the binding of highly

purified E2 (neutralizing of binding or NOB) onto cells susceptible to HCV infection; see also Example 4. Advantageously, the antibody of the invention has an NOB activity at a concentration of about 1 $\mu\text{g/ml}$, preferably at a concentration of about 0.1 $\mu\text{g/ml}$ and most preferably at a concentration of about 0.03 $\mu\text{g/ml}$.

In accordance with the present invention a screening assay that specifically allows the detection of anti-E2 antibodies capable of recognizing E2 directly expressed in cells without the requirement of antigen purification was chosen to identify and purify antibodies directed at conformation-dependent determinants. The assay was also based on expression of a genotype 1a derived antigen thus allowing for the characterization of cross-reactive anti-E2 antibodies and epitopes. Using this approach, two clones have been obtained producing anti-E2 antibodies from two HCV chronically infected patients. The first clone (clone 503) was obtained from one patient (patient 1) infected by a genotype 4 isolate while the second clone (clone 108) was derived from a second patient (patient 2) infected by a genotype 1b isolate. It could be shown that the HMabs displayed in addition a good reactivity against a genotype 1b antigen suggesting that the determinant(s) targeted by these antibodies are conserved among at least two of the main prevalent viral subtypes found in the world (subtypes 1a and 1b). In view of the above, it can be reasonably expected that the antibody of the present invention is also capable of reacting with antigens of other genotypes such as 2, 3a, 4, 5 and/or 6. The binding activity of an antibody of the invention concerning these genotypes can be easily tested in accordance with the methods as described in the examples.

The results obtained in accordance with the present invention indicate that the determinants recognized by the HMabs of the invention are targeted at conformation-dependent domains of E2 since linear determinants using different screening approaches, including peptide-scanning, Western-blot and immunofluorescence analysis using expressed truncated domains of the protein could not be identified; see Example 2. On the other hand, immunoprecipitation studies performed under reducing or non-reducing conditions indicated that the HMabs recognized a conformation-dependent-determinant. Under non-reducing conditions, these antibodies precipitated covalently as well as noncovalently

associated E1E2 complexes; see Example 3.2. The latter are thought to be functional subunits incorporated in the virion particle (Deleersnyder et al., 1997). The present data, in particular obtained from kinetic analysis of epitope formation strongly indicate that the two HMabs recognize domains of the E2 protein that appear to be folded early. Such domains would stay accessible as the protein further matures, until it adopts its final conformation characteristic of the form of E2 susceptible to be present on the surface of virions. The kinetic analysis, together with the NOB data (i.e. antibody 503, displaying NOB activity) also suggest that the two antibodies recognize different determinants; see Example 4. Alternatively, that affinity of the antibodies for the E2 protein differs.

The most encouraging result obtained in accordance with the present invention was the demonstration that one of the HMabs displayed strong NOB activity. These observations together with Rosa's et al. (Rosa et al., 1996), indicate that the determinant(s) recognized by NOB antibodies are likely directed at conformation-dependent domains of E2, domains that appear to be conserved between different genotypes. Such domains seem to be distinct from the hypervariable region 1 (HVR) that has been shown to contain neutralization epitopes. In a recent study, Zibert et al. (Zibert et al., 1997) have been able to correlate early appearance of antibodies directed at a non-conformational structure found in the HVR with acute self-limited infection. Results from the study suggests the critical existence and role of antibodies directed at a linear determinant of E2 in the control of HCV infection, observations that are in agreement with a study originally performed in the chimpanzee model by Farci et al. (Farci et al., 1996). Authors in this latter study generated a hyperimmune serum directed at a peptide from the HVR, serum that contained antibodies capable to neutralize the infectivity of a well characterized inoculum in vitro. A similar experiment was also performed by Shimizu et al. (Shimizu et al., 1996). Thus, all of these studies strongly suggest that neutralization of HCV would mostly be type-specific involving the participation of variable, non-conserved epitopes. Nonetheless, recent observations have begun to suggest the existence of other neutralization determinants, cross reactive and not directed at the HVR. In the vaccination study by Choo et al., induced neutralizing antibodies were

not directed at the HVR of E2 but apparently at other determinants carried by the antigen (Choo et al., 1994). Abrignani has recently observed a correlation between spontaneous resolution of chronic infection and appearance of high anti-NOB antibody titers (Abrignani 1997). In patients described in the Examples hereinafter, high or measurable neutralization of binding of E2 was not restricted to sera from patients infected with genotype 1a isolates, thus suggesting the existence of cross-reactive epitopes such as those described in the present application. As it was difficult to find a direct correlation between NOB titers of a purified MAb and titers found in patients' sera (both patients in our study had similar NOB serum titers > 1:1000), it was surprising that antibody 503 has an NOB activity detectable at very low concentration (0.03 μg / ml) providing for a potent activity; see Example 4.

The HMAbs produced in accordance with the present invention are expected to be useful tools to study further the biogenesis, folding and assembly of HCV glycoproteins as well as for characterization of the virion structure and a putative cell-surface receptor. As the antibody of the invention exemplified by Ab 503 represents the first HMAb described to date as having NOB activity, this antibody is particularly useful for passive immunization studies. Antibody infusion studies have demonstrated, in the case of lentiviruses, a beneficial role of administered neutralizing antibodies in the control and even the prevention of infection in different animal models (Conley et al., 1996, Emini et al., 1992, Putkonen et al., 1991).

In a preferred embodiment of the invention, said antibody is a monoclonal antibody, a polyclonal antibody, a single chain antibody, humanized antibody, or fragment thereof that specifically binds said HCV E2 glycoprotein also including bispecific antibody, synthetic antibody, antibody fragment, such as Fab, Fv or scFv fragments etc., or a chemically modified derivative of any of these. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, Nature 256 (1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals with modifications developed by the art. Furthermore, antibodies or fragments thereof to the aforementioned epitopes can be obtained by using methods

which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. When derivatives of said antibodies are obtained by the phage display technique, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of the conformation-dependent HCV glycoprotein E2 epitope (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmberg, J. Immunol. Methods 183 (1995), 7-13). The production of chimeric antibodies is described, for example, in WO89/09622. Methods for the production of humanized antibodies are described in, e.g., EP-A1 0 239 400 and WO90/07861. A further source of antibodies to be utilized in accordance with the present invention are so-called xenogenic antibodies. The general principle for the production of xenogenic antibodies such as human antibodies in mice is described in, e.g., WO 91/10741, WO 94/02602, WO 96/34096 and WO 96/33735. As discussed above, the antibody of the invention may exist in a variety of forms besides complete antibodies; including, for example, Fv, Fab and F(ab)₂, as well as in single chains; see e.g. WO88/09344. In case of bispecific antibodies where one specificity is directed to an HCV E2 glycoprotein epitope and the other preferably to a T cell antigen such as CD3, it is advantageous if the binding site recognizing the viral epitope has a high affinity in order to capture the virus or target cells which have been infected with HCV and can be destroyed with high efficiency. On the other hand, the binding affinity of the binding site recognizing, e.g., a T cell should be in the order of those of the natural T cell receptor/ligand interaction or of that usually found for the interaction of the T-cell costimulatory molecules with their receptor.

The antibodies of the present invention or their corresponding immunoglobulin chain(s) can be further modified using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination. Methods for introducing such modifications in the DNA sequence underlying the amino acid sequence of an immunoglobulin chain are well known to the person skilled in the art; see, e.g., Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y.

In a particularly preferred embodiment, the antibody of the invention comprises the amino acid sequence of the V_H and/or V_L region as depicted in Figures 5 and 6, respectively.

In a further embodiment, the present invention relates to an antigen or an epitope thereof which is recognized by an antibody of the invention. Said antigen or epitope may be glycosylated, unglycosylated or partially deglycosylated. As discussed herein and explained in the examples, the present invention feature novel antigens, recognized by the aforescribed antibodies. For the identification and isolation of antigen and epitopes of the invention, e.g., cDNA libraries can be screened by injecting various cDNAs into oocytes, allowing sufficient time for expression of the cDNA gene products to occur, and testing for the presence of the desired cDNA expression product, for example, by using the antibody of the invention.

Alternatively, a cDNA expression library in *E. coli* can be screened indirectly for peptides having at least one epitope of the invention using antibodies of the invention (Chang and Gottlieb, *J. Neurosci.*, 8:2123, 1988). After having revealed the structure of such antigens the rational design of binding partners and/or domains may be possible. For example, folding simulations and computer redesign of structural motifs can be performed using appropriate computer programs (Olszewski, *Proteins* 25 (1996), 286-299; Hoffman, *Comput. Appl. Biosci.* 11 (1995), 675-679). Furthermore, computers can be used for the conformational and energetic analysis of detailed protein models (Monge, *J. Mol. Biol.* 247 (1995), 995-1012; Renouf, *Adv. Exp. Med. Biol.* 376 (1995), 37-45).

In another embodiment the present invention relates to a polynucleotide encoding at least a variable region of an immunoglobulin chain of any of the before described antibodies of the invention. One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions or domains are together

responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions. In addition to antibodies, immunoglobulins may exist in a variety of other forms (including less than full-length that retain the desired activities), including, for example, Fv, Fab, and F(ab')₂, as well as single chain antibodies (e.g., Huston, Proc. Nat. Acad. Sci. USA 85 (1988) ,5879-5883 and Bird, Science 242(1988), 423-426); see also supra. An immunoglobulin light or heavy chain variable domain consists of a "framework" region interrupted by three hypervariable regions, also called CDR's; see supra.

The antibodies of the present invention can be produced by expressing recombinant DNA segments encoding the heavy and light immunoglobulin chain(s) of the antibody invention either alone or in combination.

The polynucleotide of the invention encoding the above described antibody may be, e.g., DNA, cDNA, RNA or synthetically produced DNA or RNA or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination. Preferably said polynucleotide is part of a vector. Such vectors may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions. Preferably, the polynucleotide of the invention is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions. In this respect, the person skilled in the art will readily appreciate that the polynucleotides encoding at least the variable domain of the light and/or heavy chain may encode the variable domains of both immunoglobulin chains or only one. Likewise, said polynucleotides may be under the control of the same promoter or may be

separately controlled for expression. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the PL, lac, trp or tac promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. Furthermore, depending on the expression system used leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the medium may be added to the coding sequence of the polynucleotide of the invention and are well known in the art. The leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a portion thereof, into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitro gene), or pSPORT1 (GIBCO BRL).

Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the immunoglobulin light chains, heavy chains, light/heavy chain dimers or intact antibodies, binding fragments or other immunoglobulin forms may follow; see, Beychok, *Cells of Immunoglobulin Synthesis*, Academic Press, N.Y., (1979); see also, e.g., the appended examples.

As described above, the polynucleotide of the invention can be used alone or as part of a vector to express the (poly)peptide of the invention in cells, for, e.g., gene therapy or diagnostics of diseases related to HCV infection. The polynucleotides or vectors of the invention are introduced into the cells which in turn produce the antibody. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors and methods for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, *Nature Medicine* 2 (1996), 534-539; Schaper, *Circ. Res.* 79 (1996), 911-919; Anderson, *Science* 256 (1992), 808-813; Isner, *Lancet* 348 (1996), 370-374; Muhlhauser, *Circ. Res.* 77 (1995), 1077-1086; Wang, *Nature Medicine* 2 (1996), 714-716; WO94/29469; WO 97/00957 or Schaper, *Current Opinion in Biotechnology* 7 (1996), 635-640, and references cited therein. The polynucleotides and vectors of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) into the cell. Preferably, said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom, most preferably said cell is a stem cell.

Furthermore, the present invention relates to vectors, particularly plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise a polynucleotide encoding a variable domain of an immunoglobulin chain of an antibody of the invention; optionally in combination with a polynucleotide of the invention that encodes the variable domain of the other immunoglobulin chain of the antibody of the invention. Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the polynucleotides or vector of the invention into targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook, *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y. (1989).

Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells. The vectors containing the polynucleotides of the invention (e.g., the heavy and/or light variable domain(s) of the immunoglobulin chains encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts; see Sambrook, *supra*.

The present invention furthermore relates to host cells transformed with a polynucleotide or vector of the invention. Said host cell may be a prokaryotic or eukaryotic cell. The polynucleotide or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally.

The host cell can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant, animal or human cell. Preferred fungal cells are, for example, those of the genus *Saccharomyces*, in particular those of the species *S. cerevisiae*. The term "prokaryotic" is meant to include all bacteria which can be transformed or transfected with a DNA or RNA molecules for the expression of an antibody of the invention or the corresponding immunoglobulin chains. Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. The term "eukaryotic" is meant to include yeast, higher plant, insect and preferably mammalian cells. Depending upon the host employed in a recombinant production procedure, the antibodies or immunoglobulin chains encoded by the polynucleotide of the present invention may be glycosylated or may be non-glycosylated. Antibodies of the invention or the corresponding immunoglobulin chains may also include an initial methionine amino acid residue. A polynucleotide of the invention can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art. Furthermore, methods for preparing fused, operably linked genes and expressing them in, e.g., mammalian cells and bacteria are well-

known in the art (Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). The genetic constructs and methods described therein can be utilized for expression of the antibody of the invention or the corresponding immunoglobulin chains in eukaryotic or prokaryotic hosts. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted polynucleotide are used in connection with the host. The expression vector typically contains an origin of replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. Furthermore, transgenic animals, preferably mammals, comprising cells of the invention may be used for the large scale production of the (poly)peptide of the invention.

Thus, in a further embodiment, the present invention relates to a method for the production of an antibody capable of recognizing a conformation-dependent epitope of Hepatitis C Virus glycoprotein E2 or a functional fragment or immunoglobulin chain(s) thereof comprising

- (a) culturing the cell of the invention; and
- (b) isolating said antibody or functional fragment or immunoglobulin chain(s) thereof from the culture,

The transformed hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth. Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like; see, Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982). The antibody or its corresponding immunoglobulin chain(s) of the invention can then be isolated from the growth medium, cellular lysates, or cellular membrane fractions. The isolation and purification of the, e.g., microbially expressed antibodies or immunoglobulin chains of the invention may be by any conventional means such as, for example,

preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies directed, e.g., against the constant region of the antibody of the invention. It will be apparent to those skilled in the art that the antibodies of the invention can be further coupled to other moieties for, e.g., drug targeting and imaging applications. Such coupling may be conducted chemically after expression of the antibody or antigen to site of attachment or the coupling product may be engineered into the antibody or antigen of the invention at the DNA level. The DNAs are then expressed in a suitable host system, and the expressed proteins are collected and renatured, if necessary.

Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the antibodies may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures.

The present invention also involves a method for producing cells capable of expressing an antibody of the invention or its corresponding immunoglobulin chain(s) comprising genetically engineering cells with the polynucleotide or with the vector of the invention. The cells obtainable by the method of the invention can be used, for example, to test the interaction of the antibody of the invention with its antigen.

Furthermore, the invention relates to an antibody of the invention or fragment thereof encoded by a polynucleotide according to the invention or obtainable by the above-described methods or from cells produced by the method described above. The antibodies of the present invention will typically find use individually in treating substantially any disease susceptible to monoclonal antibody-based therapy. In particular, the immunoglobulins can be used for passive immunization or the removal of HCV or unwanted cells or antigens, such as by complement mediated lysis, all without substantial immune reactions (e.g., anaphylactic shock) associated with many prior antibodies. For an antibody of the invention, typical disease states suitable for treatment include chronic HCV infection.

The antibodies, antigens and epitopes of the invention can be used therapeutically in, e.g., patients suffering from HCV infection. Such therapy can be accomplished by, for example, the administration of antibodies, antigens or epitopes of the invention. Such administration can utilize unlabeled as well as labeled antibodies or antigens. For example, when unlabeled the antigen or epitope is utilized advantageously, it would be in a form wherein, for example, the antigens are in fragments which are too small to stimulate an immune response, but large enough to bind, or block, the docking of HCV via E2 glycoprotein onto the target cells.

Alternatively, the antibodies, antigens and epitopes of the invention could be administered labeled with a therapeutic agent. These agents can be coupled either directly or indirectly to the antibodies or antigens of the invention. One example of indirect coupling is by use of a spacer moiety. Furthermore, the antibodies of the present invention can comprise a further domain, said domain being linked by covalent or non-covalent bonds. The linkage can be based on genetic fusion according to the methods known in the art and described above or can be performed by, e.g., chemical cross-linking as described in, e.g., WO 94/04686. The additional domain present in the fusion protein comprising the antibody of the invention may preferably be linked by a flexible linker, advantageously a polypeptide linker, wherein said polypeptide linker comprises plural, hydrophilic, peptide-bonded amino acids of a length sufficient to span the distance between the C-terminal end of said further domain and the N-terminal end of the antibody of the invention or vice versa. The above described fusion protein may further comprise a cleavable linker or cleavage site for proteinases. These spacer moieties, in turn, can be either insoluble or soluble (Diener, et al., Science, 231:148, 1986) and can be selected to enable drug release from the antigen at the target site. Examples of therapeutic agents which can be coupled to the antibodies, antigens and epitopes of the invention for immunotherapy are drugs, radioisotopes, lectins, and toxins. The drugs with which can be conjugated to the antibodies, antigens and epitopes of the invention include compounds which are classically referred to as drugs such as mitomycin C, daunorubicin, and vinblastine. In using radioisotopically conjugated antibodies,

antigens or epitopes of the invention for, e.g., immunotherapy, certain isotopes may be more preferable than others depending on such factors as leukocyte distribution as well as stability and emission. Depending on the autoimmune response, some emitters may be preferable to others. In general, α and β particle-emitting radioisotopes are preferred in immunotherapy. Preferred are short range, high energy α emitters such as ^{212}Bi . Examples of radioisotopes which can be bound to the antibodies, antigens or epitopes of the invention for therapeutic purposes are ^{125}I , ^{131}I , ^{90}Y , ^{67}Cu , ^{212}Bi , ^{212}At , ^{211}Pb , ^{47}Sc , ^{109}Pd and ^{188}Re . Other therapeutic agents which can be coupled to the antibody, antigen or epitope of the invention, as well as ex vivo and in vivo therapeutic protocols, are known, or can be easily ascertained, by those of ordinary skill in the art. Wherever appropriate the person skilled in the art may use a polynucleotide of the invention encoding any one of the above described antibodies, antigens or epitopes or the corresponding vectors instead of the proteinaceous material itself.

Moreover, the present invention relates to pharmaceutical compositions comprising the aforementioned antibody, antigen or epitope, polynucleotide, vector or cell of the invention. The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. A typical dose can be, for example, in the range of 0.001 to 1000 μg (or of nucleic acid

for expression or for inhibition of expression in this range); however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Generally, the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 μ g to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1 μ g to 10 mg units per kilogram of body weight per minute, respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10^6 to 10^{12} copies of the DNA molecule. The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the invention may comprise further agents such as interleukins or interferons depending on the intended use of the pharmaceutical composition. For example, the pharmaceutical compositions of the invention, as described above, may be administered in combination with other anti viral agents. Such agents may include, as a non limiting example, interferons, other anti HCV monoclonal or polyclonal antibodies, nucleoside analogs, inhibitors of DNA polymerase, and agents as described in Example 6. In the case of such a combination therapy the antibodies may be given simultaneously with the anti viral agent or sequentially either before or after treatment with the anti viral agent. Such

pharmaceutical compositions may also be used, for example, for immunization of liver transplantation patients to eliminate possible recurrent HCV infections in such patients. Furthermore, the pharmaceutical composition may be formulated as a vaccine, for example, if the pharmaceutical composition of the invention comprises an antigen as described above that is capable of eliciting an effective immune response against HCV. Advantageously, the pharmaceutical composition of the invention is intended for use in liver transplantation. Furthermore, it is expected that the antibody of the invention is useful for the prevention of infection of Tupaia-hepatocytes with HCV-infectious human sera.

It is envisaged by the present invention that the various polynucleotides and vectors of the invention are administered either alone or in any combination using standard vectors and/or gene delivery systems, and optionally together with a pharmaceutically acceptable carrier or excipient. Subsequent to administration, said polynucleotides or vectors may be stably integrated into the genome of the subject. On the other hand, viral vectors may be used which are specific for certain cells or tissues and persist in said cells. Suitable pharmaceutical carriers and excipients are well known in the art. The pharmaceutical compositions prepared according to the invention can be used for the prevention or treatment or delaying of HCV infection.

Furthermore, it is possible to use a pharmaceutical composition of the invention which comprises polynucleotide or vector of the invention in gene therapy. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others; see also supra. Delivery of nucleic acids to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Natl. Acad. Sci. USA 88 (1991), 2726-2729).

In a further embodiment the present invention relates to a method for preventing (re)infection of Hepatitis C Virus in a subject, comprising the step of administering the antibody, polynucleotide or vector of the invention. Further encompassed is a

method for alleviating chronic Hepatitis C in a subject, comprising the step of treating said subject using the afore-described compounds of the invention combined with a pharmaceutically acceptable carrier.

In another embodiment the present invention relates to a diagnostic composition comprising any one of the above described the antibodies, antigens, polynucleotides, vectors or cells of the invention and optionally suitable means for detection. The antigens and antibodies of the invention are, for example, suited for use in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. Examples of immunoassays which can utilize the antigen of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA), the sandwich (immunometric assay) and the Western blot assay. The antigens and antibodies of the invention can be bound to many different carriers and used to isolate cells specifically bound to said polypeptides. Examples of well-known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the invention.

There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds; see also the embodiments discussed hereinabove.

By a further embodiment, the antibodies of the invention may also be used in a method for the diagnosis of HCV infections in an individual by obtaining a body fluid sample from the tested individual which may be a blood sample, a lymph sample or any other body fluid sample and contacting the body fluid sample with an antibody of the invention under conditions enabling the formation of antibody-antigen complexes. The level of such complexes is then determined by methods known in

the art, a level significantly higher than that formed in a control sample indicating an HCV infection in the tested individual. In the same manner, the specific antigen bound by the antibodies of the invention may also be used for diagnosis of HCV infection in an individual by contacting a body fluid sample from the tested individual with the antigen as described above and determining the formation of antigen-antibody complex in the sample. Thus, the present invention relates to an in vitro immunoassay for the presence of Hepatitis C Virus glycoprotein E2, characterized by measuring its co-precipitation with the antibody of the invention, preferably under non-reducing conditions. Furthermore, the present invention encompasses a method for diagnosing chronic Hepatitis C in a subject, characterized in that samples of said subject are tested using the antibody of the invention for the presence of neutralization of binding of Hepatitis C Virus glycoprotein E2 onto target cells. Accordingly, the present invention also involves a neutralization assay for inhibiting the binding of Hepatitis C Virus glycoprotein E2 onto target cells using the antibody of the invention.

The present invention also comprises methods of detecting the presence of HCV antigen in a sample, for example, a cell sample, which comprises obtaining a cell sample from a subject, contacting said sample with one of the aforementioned antibodies, preferably under non-reducing conditions permitting binding of the antibody to the antigen, and detecting the presence of the antibody so bound, for example, using immuno assay techniques such as radioimmunoassay or enzymeimmunoassay. Furthermore, the present invention relates to a method for detecting autoantibodies against Hepatitis C Virus in a subject comprising contacting a sample from a subject with the antigen of the invention, and detecting the presence of antibodies bound to said antigens.

In a still further preferred embodiment the present invention relates to the use of the afore-described antibody, antigen, polynucleotide, vector or cell for the preparation of a pharmaceutical composition for the treatment or prevention of HCV infection in a subject or for the prevention of recurrence of HCV infection. Preferably said

pharmaceutical composition is designed to be administered prior, during or after liver transplantation.

The pharmaceutical compositions, methods and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the methods and uses described herein.

These and other embodiments are disclosed and encompassed by the description and Examples of the present invention. Further literature concerning any one of the antibodies, methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries and databases, using for example electronic devices. For example the public database "Medline" may be utilized which is available on the Internet, for example under <http://www.ncbi.nlm.nih.gov/PubMed/medline.html>. Further databases and addresses, such as <http://www.ncbi.nlm.nih.gov/>, <http://www.infobiogen.fr/>, http://www.fmi.ch/biology/research_tools.html, <http://www.tigr.org/>, are known to the person skilled in the art and can also be obtained using, e.g., <http://www.lycos.com>. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only and are not intended to limit the scope of the invention.

The Figures show:

Figure 1: Indirect immunofluorescence analysis. CV-1 cells were infected with the SVE2 recombinant virus as previously described (Fournillier-Jacob et al., 1996) and immunofluorescence analysis performed using patients's sera (1: 20 dilution) or supernatants from the HMABs

producing cell lines. Staining was performed using goat-anti human IgG immune serum coupled with fluoresceine. (A) serum from patient 1; (B) serum from patient 2; (C) HMAb 503 ; (D) HMAb 108; (E) serum from a patient with chronic hepatitis unrelated to HCV. An additional negative control (F) included CV-1 cells transfected with a SVE1 recombinant virus (expressing E1) and stained with the HMAb 503 or 108 (result is shown for HMAb 503 only).

Figure 2: Plasmids used in the epitope mapping studies. (A) Representation of the HCV genomic domain coding for the viral nucleocapsid (C), the glycoproteins E1 and E2 and the non-structural proteins p7, NS2 and NS3 (Rice et al., 1996). Amino acid position of the proteolytic cleavage sites are indicated. (B) Map position and amino acid boundaries of the sequences encoded by the different expression plasmids.

Figure 3: Immunoprecipitation of E2 and co-precipitation of E1 and analysis of epitope formation under reducing and non-reducing conditions. Cells coinfecting with vTF7-3 and vHCV1-1488 (vHCV) or with TF7-3 alone (M) were pulse labeled for 5 min and chased for the indicated times (in hours). The E2 glycoprotein was immunoprecipitated with HMABs 108, 503 and mouse MABs H2 (Deleersnyder et al., 1997) and A11 (Dubuisson et al., 1994). Immunoprecipitates were analyzed under reducing or nonreducing conditions by SDS-PAGE (10% acrylamide). Expected position of HCV specific proteins are indicated at the left of the figures.

Figure 4: Percent neutralization of E2 binding by HCV-E2 HMABs. Various concentrations of anti-E2 HMABs 503 and 108 were tested for their ability to neutralize binding of purified CHO expressed E2 protein onto MOLT-4 cells. Neutralization was calculated as described (Rosa et al., 1996) and 50% neutralization titers are indicated.

Figure 5: Nucleotide and amino acid sequences of the variable region of the light chain (V_L) of HMAb 503.

Figure 6: Nucleotide and amino acid sequences of the variable region of the heavy chain (V_H) of HMAb 503.

The Examples illustrate the invention.

Example 1: Patients' screening and generation of human monoclonal antibody producing B cells (LCLs)

Two patients were enrolled in the study. HCV infection was determined by the RIBA III assay (Abbott Laboratories). At time of PBMC (peripheral blood mononuclear cells) immortalization, both patients had chronic hepatitis as determined by histological examination and positive PCR assays. Serum viral loads were determined using the bDNA assay version 2.0 (quantiplex HCV RNA Assay, Chiron Diagnostics). HCV genotypes were determined using three different methods. The first one was based on the detection of genotype-specific antibodies directed at the nonstructural antigen 4 (NS4) and was determined using the MUREX 1-6 serotyping assay according to the manufacturer's instruction (MUREX Diagnostics SA, Bhattacharjee et al., 1995). The second one was based on the amplification of viral sequences from the 5'non-coding region (NCR) of the genome using genotype/subtype specific primers and was performed using the INNO-LIPA assay (Innogenetics S.A.). In one of these two patients, patient 1, despite detectable HCV RNA by PCR in the serum, serum ALT (alanine amino transferase) levels were and remained normal (mild hepatitis). In contrast, ALT levels remained persistently elevated in patient 2 and infection in this patient was characterized by cirrhosis.

Generation of HMABs producing cell lines was performed as previously described (Boyer et al., 1991, Desgranges et al., 1988, Seigneurin et al., 1983). Briefly, after Ficoll isolation, PBMCs were exposed to EBV culture supernatant (1 ml of B95.8 strain supernatant with a titer of 10^{-3} TD50/ ml for 5×10^6 PBMCs) at room

09744176-061801

temperature. After incubation, they were diluted in medium at concentration ranging from 50 to 100 x 10³ cells per well. After 2 to 4 weeks, the supernatants were screened for anti-E2 reactivity by the SVE2 CV-1 IFA. Detection of anti-E2 antibodies has been reported to be tightly dependent on the antigen production method (Chien et al., 1993, Hsu et al., 1993, Lesniewski et al., 1995). Eukaryotic but not prokaryotic expression of HCV E2 has been shown to allow for proper processing and glycosylation of the protein (Selby et al., 1993). In our study, we used as screening assay for anti-E2 antibodies an eukaryotic expressed E2 antigen analyzed under a native form i.e. visualized by an immunofluorescence assay (IFA). Such a detection assay has been previously used by Fournillier-Jacob et al., and shown to be particularly efficient for antibody detection (Fournillier-Jacob et al., 1996). Briefly, a recombinant plasmid, pCW18 E2, expressing HCV E2 amino acid sequence 371 to 746 from the prototype strain H (genotype 1a) was used to transfect CV-1 cells together with a helper SV40 mutant virus to generate the stock of recombinant virus expressing E2 (SVE2, Fournillier-Jacob et al., 1996, Wychowski et al., 1986). SVE2 virus was used to further infect CV-1 cells and immunofluorescence analysis were performed using sera from infected patients and supernatants from EBV-immortalized B cells as previously described (Fournillier-Jacob et al., 1996). Cells were fixed in methanol: acetone (3: 7) prior to analysis.

LCLs were further subcloned twice at 2 to 20 cells per well with 50 x 10³ irradiated (2,500 rads) allogenic PBMCs. Two persistently positive clones derived from the two patients were obtained. Table 1 summarizes characteristics of the two patients and of the two lymphoid B-cell lines producing HMAbs, designated 503 and 108. Analysis of culture supernatants from the two clones revealed that both clones secreted IgG1 only. Supernatants from each clone were tested by IFA on CV-1 cells infected with the recombinant SVE2 virus and staining was revealed using specific secondary antibodies for human IgM, IgG or IgA (Byosis), IgG1, IgG2, IgG3 and IgG4 subclasses (Sigma Immuno Chemical Co.) and for λ and κ light chains (Dakopatts).

Table 1. Characteristics of patients and derived human anti-E2 monoclonal antibodies

Patients	Genotype ^a	Viral load ^b Eq/ml x 10 ⁵	Histological diagnosis	HMAbs	Isotype ^c
1	4	5.2	Mild Chronic Hepatitis	503	IgG1 λ
2	1b	21.8	Cirrhosis	108	IgG1 λ

27

^a Analysis were made with samples derived from the day of patients' EBV-PBMC transformation as well as from two different time points during a two year follow-up. Results at the different time points and between the different assays were concordant.

^b Quantified in serum with the Quantiplex bDNA assay (Quantiplex HCV RNA Assay, Chiron Diagnostics, Emeryville).

^c Supernatants from each clone were tested by IFA on CV-1 infected cells with the recombinant SVE2 virus and staining was revealed using specific secondary antibodies for human IgM, IgG, IgA, IgG1-4 subclasses

A protein A (Pharmacia) column was used for affinity purification of supernatant producing HMabs. The determination of antibody concentration in culture supernatants was performed by ELISA as previously described (Boyer et al., 1991). LCLs produced 2 to 5 μ g of Ab/ml of conventional culture medium. Genotyping of patient 1 and 2 infecting viruses was at time of PBMC immortalization and on two times within the past two years prior to the immortalization using two different assays. Both assays gave concordant results and indicated that patient 1 was infected by a genotype 4 isolate while patient 2 was infected by a genotype 1b isolate. As commercially available HCV genotyping assays may be lacking specificity and in order to exclude the possibility of dual infection, we further confirmed the above results by the analysis of PCR-derived sequences mapping within the 5'non-coding region of the HCV genome. Nucleotide sequences derived from cloned quasispecies was compared to published databases (Bukh et al., 1992) and the results confirmed those obtained with the commercial genotyping assays i.e. that both patients were infected with a single viral type. Figure 1 illustrates the staining of SVE2 infected CV-1 cells observed in the IFA using the patients' sera (A and B) or the purified monoclonal antibodies (C and D). The reactivity was localized in the cytoplasm with a predominant perinuclear distribution.

Example 2: Immunological characteristics of the HMabs

Different approaches were used to characterize the immune reactivity of the produced antibodies. Western blot analysis using denaturing conditions and protein preparations containing subtype 1a or 1b derived E2 proteins (Nakano et al., 1997) were performed using the original patients' sera, supernatants from the LCLs as well as purified antibodies. For Western blotting analysis, baculovirus expressed E2 proteins from a genotype 1a and 1b sequence were used as previously described (Nakano et al., 1997). Patients' sera (1:50), supernatants from the two clones as well as purified HMabs (tested at a concentration as high as 10 μ g/ml) were used. Epitope mapping using patient's sera as well as purified antibodies was performed using a panoply of synthetic peptides covering the entire E2 open reading frame as

previously described (Courtesy A.M. Prince, Wang et al., 1996). The synthetic peptides were mostly 12-mer with 6 aa overlap between successive peptides, corresponding to the sequences of HCV-H strain (genotype 1a) E2 protein. There were a total of 57 peptides for E2 (aa 384-727), all of which were synthesized by AnaSpec.

While sera of both HCV infected patients reacted with the E2 1a and 1b derived proteins, none of the culture supernatants or purified HMABs gave a positive signal, even when tested at concentrations as high as 10 µg/ml. No reactivity could either be observed when culture supernatants or purified antibodies were tested in a peptide scanning ELISA using a panel of synthetic peptides covering a E2 1a sequence.

As the above observations suggested that the recognized determinants may be of non-linear nature, immune reactivity of the different samples was analyzed in IF assays. Cells were transfected with a panoply of plasmids expressing different domains of E2 (see Figure 2) in order to try and identify restricted determinant sequences. The two HMABs obtained were evaluated for reactivity by IFA on LTK cells transfected by a panoply of vectors expressing truncated domains of the E2 protein (see Figure 2). E2 sequences were cloned directly under the CMV promoter of the pcDNA3 plasmid (Promega) for plasmids pCIE2 and pCIE2t or expressed as fusion proteins with the hepatitis B virus surface antigens for plasmids pS2S.E2A-E using standard techniques and as previously described (Sambrook et al., 1989, Nakano et al., 1997). All DNA preparations were generated using Qiagen purification columns (Qiagen) according to the manufacturer's instructions. LTK cells were transfected using 1.0 µg of DNA in presence of Lipofectamine (Gibco BRL). The immune-reactivity of cell supernatants and of purified HMABs were tested by IFA at 48 hours post infection as previously described (Major et al., 1995). Positive control included the use of a reactive hyperimmune serum generated from mice immunized by the direct injection of the plasmid pCIE2t (Nakano et al., 1997). Negative controls included the use of uninfected LTK cells as well as CV-1 cells infected with a recombinant SV40 virus expressing E1 (Fournillier-Jacob et al., 1996).

Table 2 : Immune reactivity of patients' sera and of purified monoclonal antibodies (HMAbs) against truncated domains of E2

HCV constructs ^a	A	B	C	D	E	pCIE2 α	pCIE2t	pcDNA3
Patient 1 ^b								
serum	+	-	+	-	-	+	+	-
HMAb 503	-	-	-	-	-	-	+	-
Patient 2 ^c								
serum	-	-	-	-	-	-	+	-
HMAb 108	-	-	-	-	-	-	+	-
Mouse polyclonal Ab ^d	+	+	+	+	+	+	+	-

^a LTK cells were transiently transfected with the indicated plasmids and IFA performed 48 hrs later as described in Major et al., (Major et al., 1995). The pS2.SE2A-E plasmids are according to Nakano et al., (Nakano et al., 1997). The pcDNA3 plasmid (Promega) was used as a negative control.

^b Patients' sera were tested at 1 / 20 dilution; supernatants of LCLs or purified HMAbs were used at a concentration up to 10 μ g / ml in at least two independently performed experiments.

^c The efficiency of transfection and proper expression of the plasmids was evaluated in all cases using a reactive hyperimmune serum obtained from mice immunized by direct injection of the plasmid pCIE2t (Nakano et al., 1997).

Results of the IF studies are summarized in Table 2. Serum of patient 1 recognized multiple determinants mapping within the sequences expressed from various E2-expressing plasmids. In contrast, the HMAb 503 derived from this patient recognized only the near full-length expressed form of E2 (encoded by plasmid pCIE2t) but none of the smaller expressed forms of the antigen. For patient 2, the serum as well as the derived 108 antibody reacted only against the largest expressed form of E2. Thus, using this approach it was not possible to identify restricted determinant sequences recognized by either of the purified antibodies.

All the above experiments involved a subtype 1a derived antigen. It was evaluated the capacity of the purified monoclonal antibodies to, in addition, recognize a subtype 1b derived E2 as a way to evaluate their cross-reactive potential. Reactivity of the HMABs was tested by immunoprecipitation using cells infected with a recombinant Sindbis virus, Sinrep/HCV-BK1-1207, expressing such an antigen. Both antibodies were capable of recognizing the antigen as shown by the observation of strong, specific signals.

Taken together with the above results, these data suggest that the HMABs are capable to recognize determinants specific of at least two different E2 subtype (1a and 1b) derived antigens. In addition, they strongly suggest that the antibodies are likely to recognize conformation-dependent determinants.

Example 3: Immunoprecipitation studies

The absence of reactivity of the HMABs in western blotting and by IFA on LTK cells transfected by a panel of vectors expressing different truncated parts of E2 suggests that the Abs recognize conformation-dependent epitope(s). Therefore, it was further evaluated the recognition of E2 by the HMABs in pulse chase experiments. In addition, as previous reports have suggested that E1 and E2 interact to form complexes which have been proposed to be functional subunits incorporated in the virion particles (Deleersnyder et al., 1997), the ability of the HMABs to recognize such complexes was also evaluated. These E1E2 complexes are noncovalently associated or stabilized by intramolecular disulfide bonds forming E1E2 aggregates.

Covalently associated E1E2 complexes have also been reported that are not believed to be part of the functional subunits of the viral particles (Dubuisson et al., 1994, Grakaoui et al., 1993, Ralston et al., 1993). For the purpose of the present invention, different recombinant viruses were used. These included: 1) a recombinant vaccinia virus vTF7.3 expressing the T7 DNA-dependent RNA polymerase (Fuerst et al., 1986), 2) a panoply of recombinant vaccinia viruses expressing HCV-H amino acid sequences, vHCV 170-809, vHCV 371-809, vHCV 1-1488 and vHCV 370-661 (Grakoui et al., 1993, Michalak et al., 1997, Fournillier-Jacob et al., 1996, Major et al., 1995) and 3) a recombinant Sindbis virus (Sinrep/HCV-BK1-1207) expressing the structural proteins of a genotype 1b strain, the BK strain (Dubuisson et al., 1994). Viral stocks were generated in CV-1 monolayers (for the vaccinia viruses) or in BHK-21 cells (for the Sindbis virus) as described (Dubuisson et al., 1994, Bredenbdeek et al., 1993). Cells were infected and metabolically labeled with 35S-translabel (ICN) as previously described (Dubuisson et al., 1994, Dubuisson and Rice, 1996). Cells were lysed with 0.5% NP-40 in 10 mM Tris-HCl (ph 7.5), 150 mM NaCl, and 2 mM EDTA. Twenty mM iodoacetamide was included in the lysis buffer for experiments in which disulfide bond formation was assayed. Immunoprecipitations were carried out as described (Dubuisson et al., 1994, Dubuisson and Rice, 1996). For quantitative experiments, autoradiographs were analyzed by densitometry.

3.1 The HMABs recognize an early folded domain of E

Immunoprecipitations were performed to characterize the proteins recognized by these HMABs (Figure 3). Murine anti-E2 MABs directed at conformation-independent (MAB A11) or conformation-dependent (MAB H2) epitopes were used for comparison (Dubuisson et al., 1994, Deleersnyder et al., 1997). Under reducing conditions, HMABs 108 and 503 did not precipitate the E2 protein during the pulse, but after 30 min of chase a band corresponding to E2 started to be detected with an increased intensity after 60 min (Figure 3, Reducing HMABs 108 and 503). This is in contrast with results obtained using the murine MAB A11 directed at a conformation-

independent epitope (Figure 3, Reducing, MAb A11). As previously observed with this latter antibody, heterogeneous E2 related products were detected during the pulse probably as a consequence of a translational pause during the synthesis of the NS2 region in the E2-NS2 precursor (Dubuisson et al., 1996). For the MAb A11, the intensity of the E2-NS2 precursor precipitated was very high after 30 min of chase and decreased with time whereas it was low and rather constant for the E2-NS2 protein precipitated by the HMABs 108 and 503, indicating that E2 was mainly precipitated by the Abs after its cleavage from the E2-NS2 precursor. Comparison with immunoprecipitation performed with the conformation-dependent MAb H2 indicated a greater delay in the detection of E2 (Figure 3, Reducing, MAb H2). These observations indicate that indeed the HMABs recognize a conformation-dependent domain of E2 which appears early during the maturation process of the E2 protein. The estimated half-time of epitope formation for both HMABs was around 15 min (data not shown).

3.2 The HMABs can precipitate noncovalent E1E2 complexes

Additional pulse chase experiments were performed under non-reducing conditions and compared with those performed under reducing conditions (Figure 3). While under reducing conditions, both HMABs coprecipitated E1 indicating that they recognize E1 and E2 complexes, when immunoprecipitations were performed under non-reducing conditions which prevent the disulfide bonds stabilizing E1E2 complexes, slow migrating bands were also detected on the top of the gels. These latter observation suggests that the E1E2 complexes precipitated consisted of noncovalently associated heterodimers and heterogeneous linked aggregates. As previously observed, for MAb H2 which has been shown capable to recognize a native form of E2, only bands corresponding to E1 and E2 were detected on the gel in that case (Figure 3, non-reducing, H2, Deleersnyder et al., 1997). Under non-reducing conditions, the coprecipitation of the E1 monomeric form with HMAb 108 was poorer, with a specific band detected only after a long exposure time as compared with HMAb 503. Thus, both HMABs recognize domain(s) of the E2 protein

that appear folded early and would stay accessible as the protein adopts its final conformation as suggested by the coprecipitation of noncovalently associated E1E2 complexes.

All together, the above data indicate that both HMABs 108 and 503 recognize a conformation-dependent determinant (or determinants) and could precipitate E1 and E2 noncovalently associated complexes which are believed to exist on the virion particle.

Example 4: Neutralization of E2 binding onto cells

The assay recently developed by Rosa et al., (Rosa et al., 1996) allows to evaluate, in a quantitative fashion, the ability of candidate antibodies to neutralize the binding of highly purified E2 (neutralizing of binding or NOB) onto cells susceptible to HCV infection. Both HMABs were evaluated in this assay. The ability of the HMABs was assessed to neutralize the binding (Neutralization of Binding or NOB) of E2 to MOLT 4 cells in the assay recently developed by Rosa et al. (Rosa et al., 1996). The assay was run in 96 U-bottom microplates. Briefly, twenty μ l of recombinant CHO E2₃₈₄₋₇₁₅ proteins at 0.5 μ g/ml was mixed with various dilution of anti-E2 HMABs and control HMABs (Rosa et al., 1996, Boyer et al., 1991). After incubation at 4°C for 1 h, the mixture was added to MOLT-4 cells (105 cells per well). After washing, cells were subsequently incubated with 1/100 dilution of human serum with anti-E2 immunoglobulins which recognizes E2 bound to target cells. Cells were washed and incubated with fluoresceine isothiocyanate-conjugated antiserum to IgG. Fluorescence was analyzed with a FACScan flow cytometer. Specific neutralization was calculated as follow: $((\text{positive control MFI} - \text{experimental MFI}) / (\text{positive control MFI} - \text{negative control MFI})) \times 100$ where (MFI) = mean fluorescence intensity of the cell population which directly relates to the surface density of fluorescently labeled HCV proteins bound to the cells. MFI values of cells incubated with or without HCV proteins and with the HCV HMABs or HCV-negative HMABs or pre-immune sera (Rosa et al., 1996) are compared. The threshold of positivity is set for each experiment by flow cytometric analysis of cells without HCV proteins bound that

have been incubated with antisera to HCV proteins and the fluorescein isothiocyanate-labeled second antibody. For competition binding analysis, antibodies were biotinylated as followed: 1 mg / ml of the antibodies in 0.4 M phosphate buffer were incubated with N-N- dimethylformamide biotin at 2 mg / ml at 4° C for 2 hrs and dialyzed extensively against PBS overnight. Testing of the NOB activity was performed using both antibodies, the competitor labeled antibody being used at 2.5 µg/ml.

Percent neutralization obtained at different concentrations of the antibodies are shown in Figure 4. The results indicate that the HMAb 503 displayed NOB activity and that fifty percent neutralization of binding was achieved at a concentration of 0.03 µg/ml. No NOB activity could be detected for HMAb 108 at any of the concentration tested. Hence, the HMAb 503 that is capable of NOB activity is the first such antibody described to date. Interestingly, the fact that the producing clone (503) was derived from a genotype 4 infected patient while the assay used a genotype 1(a) derived antigen confirms the cross-reactive potential of this antibody. The data also suggest that antibodies with NOB-activity seem to be targeted at determinants conserved between different viral genotypes.

Competition experiments were performed to determine whether the two antibodies binds to similar or topographically distinct epitopes. The HMAb 108 did not prevent (i.e. did not compete) the detection of the neutralizing activity of the 503 Ab. These results strongly suggest that the HMABs 108 and 503 recognize different epitopes on the E2 protein.

Example 5: Prevention of HCV infection in liver transplantation

The following describes a liver transplantation in the case of an infection with hepatitis C virus (HCV), whereby an antibody of the invention is administered in order to avoid a re-infection of the implanted organ.

Preparation of the patient: shaving of the whole body, clystering, taking blood (quantitatively determining HCV-RNA), decontamination of the intestine with the help of drugs.

Preparation of the donor (death of the brain certified, heart is still beating): taking blood (checking for antibodies against hepatitis B, C; HIV, cytomegalovirus), removal of the organ, conservation for the transport to the University of Wisconsin in a conservation medium (electrolyte solution rich in kalium, kept at a temperature of 4°C) and transport to the patient. The patient is given general anesthesia + immunosuppression in the O.R. (approx. 1 g prednisolone + FK 506 or cyclosporine A + optionally azathioprine + optionally antithymocyte globulin); stomach is opened (laparotomy); a bypass is fixed between vena femoralis (ridge) and vena axillaris (axilla) in order to stabilize the blood circulation; the liver is removed from the surrounding tissue, afferent and efferent vessels are prepared (arteria hepaticae, vena portae, ductus choleductus, vena hepaticae) and the liver is mobilized (*Pringle-Manöver*). The vessels are clamped and the liver is removed.

At this stage, the antibody is administered: 100-200 mg antibody + 500 mg human serum albumin as a lyophilisate or as a concentrated solution are dissolved in 100 ml isotonic salt solution or in a 5% glucose solution and infused in the course of two hours. During the infusion the donor organ is placed into the patient's abdominal region. The vessels are anastomosed (sutured), and again a blood probe is taken (determination of HCV-RNA-titer). After the infusion has been terminated, the vessels are re-perfused and checked for closeness. If they are closed, the liver is placed in the abdominal region. One hour after the perfusion was started, a biopsy of the liver is taken and the abdomen is closed. The biopsy is immunohistochemically analyzed if the antibody has reached a target.

The patient is brought to the intensive care unit, kept under anaesthetic and artificially ventilated. Liver function, secondary hemorrhages, vascular occlusion, stage of the infection, antibody concentration as well as HCV-RNA-titer in the blood are closely monitored (normal course of the HCV-RNA-titer: after several days below demonstration level it increases after approx. one week).

Long-term course: In the first period of time 100 mg prednisolone per day are administered, the dose is decreased to 5 mg in the course of three month; prednisolone as well as individual doses of FK506 or cyclosporine are administered for the whole life, azathioprine and/or antithymocyte globulin only in the first four weeks. The therapeutic antibody will probably be renewed every six to eight weeks (infusion 100-200 mg); the HCV-RNA titer and the concentration of the antibody will be determined every four weeks. If there is known more about the antibody, the measurement will not be necessary anymore. Liver function, infections and possible rejection reactions (biopsy) are monitored for the whole life. Preexposure prophylaxis (partners of infected people; usually protection by the use of condoms if no pregnancy is desired): Every six to eight weeks bolus of 100-200 mg antibody intramuscularly (if sufficiently acceptable) or via infusion. Monitoring of the antibody concentration in the blood.

For postexposure prophylaxis (nurse who has stung herself with a needle etc.) blood is taken (HCV-RNA-titer is determined), before result is there, 100-200 mg antibody are given via infusion.

Example 6: Cloning and determination of functional immunoglobulin variable region sequences of the human anti-HCV antibody and expression in CHO-cells

Total RNA was prepared from the antibody producing EBV-transformed human B cell line according to Chomczynski (Analytical biochemistry 162 (1987) 156-159).

Subsequently, cDNA was synthesized according to standard protocols (Sambrook, Cold Spring Harbour Laboratory Press 1989, second edition).

The DNA-regions that encode the lambda-light chain and the γ 1-heavy chain Fd-segment (VH+CH1) of the human anti-HCV antibody were amplified by PCR using the oligonucleotide primer set listed in Table 3 and the cDNA synthesized from said human B cell line as template.

This primer set gives rise to a 5'- *Xho*I and a 3'- *Spe*I recognition site for the heavy chain Fd-fragment and to a 5'-*Sac*I and a 3'- *Xba*I recognition site for the lambda light chain. For the PCR-amplification of the heavy chain Fd-encoding DNA-fragment five different 5'-VH-primers (VH1,3,5,7, VH2, VH4, VH4B and VH6) were each combined with the 3'-VH primer CGd1; for the PCR-amplification of the lambda light chain fragment eight different 5'-VL primers (VL1-8) were each combined with the 3'-VL primer CL2.

The following PCR programm was used for amplification: Denaturation at 94 °C for 20 sec.; primer annealing at 52°C for 50 sec. and primer extension at 72 °C for 60 sec. for 40 cycles, followed by a 10 min. final extension at 72°C.

PCRs were run on agarose gel and DNA bands of the appropriate size isolated. Each isolated DNA band was subsequently digested with the restriction enzymes *Xho* I and *Spe* I (in case of heavy chain fragments) or with *Sac* I and *Xba* I (in case of light chain fragments) and cloned into the plasmid vector Bluescript (Stratagene) that was either prepared by digestion with *Xho* I and *Spe* I or by cleavage with *Sac* I and *Xba* I.

Plasmid preparations of cloned heavy- and light chain fragments were subsequently subjected to sequence analysis. Two sequences were selected that encode for functional immunoglobulin heavy- and light chain variable regions (VH and VL), respectively; exactly one functional VH- and one functional VL-region could thus be identified. Functional VL- and VH-sequences are depicted in Figures 5 (SEQ ID NOS: 1 and 2) and 6 (SEQ ID NOS: 3 and 4). The amino acid sequence of the mature N-terminus was each completed by comparison with the corresponding germline sequences as provided by a Human V Gene Sequence databank (<http://www.mrc-cpe.cam.ac.uk/imt-doc/>).

Cloning and sequencing was carried out according to standard methods (Sambrook, Cold Spring Harbour Laboratory Press 1989, second edition).

In order to clone VL- and VH-fragments that contain the original N-termini of heavy and light chain of the human anti-HCV antibody, the following experimental procedure was carried out:

The total RNA was reverse transcribed with the MMLV reverse transcriptase Superscript II (Gibco BRL, Eggenstein) according to standard protocols (Sambrook, Cold Spring Harbour Laboratory Press 1989, second edition). Specific priming of cDNA was carried out with the two oligonucleotides CGd1 (for the heavy chain) and CL2 (for the light chain).

The first strand of cDNA was then poly-G tailed using terminal transferase (Pharmacia, Freiburg) according to standard protocol. The tailed cDNA was PCR-amplified using a sense primer containing a poly-C stretch, based on the anchor primer sequence published by Gilliland, L. K. et al., (Tissue Antigens 47, 1-20, 1996) and designated 5'-AncTail (CGTCGATGAGCTCTAGAATCCCCCCCCCCCCCD). This anchor primer was combined with an antisense primer, specific for the nucleotide sequence encoding the C-terminus of the lambda light chain constant region (CL2) or that of the IgG1-CH1 heavy chain domain (CGd1), respectively.

The PCR was carried out as follows: Primary denaturation: 94°C for 4 min.; 30 cycles of amplification: 93°C for 30 sec.; 55°C for 30 sec.; 72°C for 30 sec.; terminal elongation: 72°C for 3 min. Each of these primers contain a restriction enzyme cleavage site (5'-AncTail: *EcoRI*; CL2: *XbaI*; CGd1: *SpeI*) which allows cloning of the corresponding PCR-fragments into a plasmid vector digested with *EcoRI/XbaI* or *EcoRI/SpeI*, respectively; for this purpose the bluescript KS+ plasmid vector (Genebank Accession No X52327) was used, since it also allows easy sequence analysis of the resulting inserts by using common sequencing primers. Several clones of heavy and light chain fragments proved to have identical sequences, respectively and could be identified to encode either functional VL- or VH-regions. The VH-sequence proved to be identical with that cloned by the above mentioned method. The amino acid sequence of VL (SEQ ID NO: 6) turned out to carry one amino acid replacement at position 2 of the mature N-terminus, compared to the VL-sequence obtained by the above mentioned method.

The complete lambda light chain including the native leader peptide, was cloned according to standard procedures via PCR into the mammalian expression vector pEF-ADA (see PCT/EP98/02180). VH was also cloned according to standard

procedures via PCR into the genomic context of a human γ 1-heavy chain in the mammalian expression vector pEF-DHFR as described in PCT/EP98/02180.

Expression of the complete human IgG1 λ -antibody was performed by stable transfection of CHO-cells and subsequent gene amplification as described (PCT/EP98/02180). Purification of the antibody from cell culture supernatant was carried out by Protein A affinity chromatography as described in PCT/EP98/02180.

Table 3: List of primers

5'-VH primer set:

VH1,3,5,7: AGGTGCAGCTGCTCGAGTCTGG
 VH2: CAG(AG)TCACCTTGCTCGAGTCTGG
 VH4: CAGGTGCAGCTGCTCGAGTCGGG
 VH4B: CAGGTGCAGCTACTCGAGTGGGG
 VH6: CAGGTACAGCTGCTCGAGTCAGG

3'-VH primer:

CGd1 GCATGTACTAGTTTTGTCACAAGATTTGG

5' VL primer set:

VL1: AATTTTGAGCTCACTCAGCCCCAC
 VL2: TCTGCCGAGCTCCAGCCTGCCTCCGTG
 VL3: TCTGTGGAGCTCCAGCCGCCCTCAGTG
 VL4: TCTGAAGAGCTCCAGGACCCTGTTGTGTCTGTG
 VL5: CAGTCTGAGCTCACGCAGCCGCCC
 VL6: CAGACTGAGCTCACTCAGGAGCCC
 VL7: CAGGTTGAGCTCACTCAACCGCCC
 VL8: CAGGCTGAGCTCACTCAGCCGTCTTCC

3' VL primer:

CL2: CGCCGTCTAGAATTATGAACATTCTGTAGG

REFERENCES

- Abrignani, Springer Semin. Immunopathol. 19 (1997), 47-55.
- Akatsuka, Hepatology 18 (1993), 503-510.
- Bhattacharjee, J. Gen. Virol. 76 (1995), 1737-1748.
- Bergeron, Trends Biochem. Sci. 19 (1994), 124-129.
- Boyer, Clin. exp. Immunol. 83 (1991), 452-459.
- Bredenbeek, J. Virol. 67 (1993), 6439-6446.
- Bukh, Proc. Natl. Acad. Sci. USA. 89 (1992), 4942-4946.
- Cerino, J. Immunol. 147 (1991), 2692-2696.
- Cerino, J. Immunol. 151 (1993), 7005-7015.
- Chan, J. Gen. Virol. 77 (1996), 2531-2539.
- Chien, Lancet 342 (1993), 933.
- Choo, Science 244 (1989), 359-362.
- Choo, Proc. Natl. Acad. Sci. USA. 91 (1994), 1294-1298.
- Conley, J. Virol. 70 (1996), 6751-6758.
- Deleersnyder, J. Virol. 71 (1997), 697-704.
- Desgranges, Lancet, 8591 (1988), 935-936.
- Dubuisson, J. Virol. 68 (1994), 6147-6160.
- Dubuisson, J. Virol. 70 (1996), 778-786.
- Emini, Nature 355 (1992), 728-730.
- Farci, Proc. Natl. Acad. Sci. USA. 91 (1994), 7792-7796.
- Farci, Proc. Natl. Acad. Sci. USA. 93 (1996), 15394-15399.
- Fournillier-Jacob, J. Med. Virol. 50 (1996), 159-167.
- Fournillier-Jacob, J. Gen. Virol. 77 (1996), 1055-1064.
- Fouts, J. Virol. 71 (1997), 2779-2785.
- Francki, Arch. Virol. 2 (1991), 223-233.
- Fuerst, Proc. Natl. Acad. Sci. USA. 93 (1986), 8122-8126.
- Gakoui, J. Virol. 67 (1993), 1385-1395.
- Hsu, Hepatology 17 (1993), 763-771.
- Fuerst, Proc. Natl. Acad. Sci. USA. 83 (1986), 8122-8126.

- Lesniewski, J. Med. Virol. 45 (1995), 415-422.
- Lanford, Virology 197 (1993), 225-235.
- Major, J. Virol. 69 (1995), 5798-5805.
- Michalak, J. Gen. Virol. 78 (1997), 2299-2306.
- Miller, Proc. Natl. Acad. Sci. USA. 87 (1990), 2057-2061.
- Miyamura, Trends Microbiol. 1 (1993), 229-231.
- Mondelli, J. Virol. 68 (1994), 4829-4836.
- Nakano, J. Virol. 71(1997), 7101-7109.
- Putkonen, Nature 352 (1991), 436-438.
- Ralston, J. Virol. 67 (1993), 6753-6761.
- Rice, Fields Virology, Third edition. Raven Press, New York (1996).
- Rosa, Proc. Natl. Acad. Sci. USA. 93 (1996), 1759-1763.
- Saito, Proc. Natl. Acad. Sci. USA. 87 (1990), 6547-6549.
- Sambrook, Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York (1989).
- Seigneurin, Science 221 (1983), 173-175.
- Selby, J. Gen. Virol. 74 (1993), 1103-1113.
- Shimizu, J. Virol. 68 (1994), 1494-1500.
- Shimizu Virology 223 (1996), 409-412.
- Weiner, Virology 180 (1991), 842-848.
- Wang, J. Inf. Dis. 173 (1996), 808-821.
- Wychowski, EMBO J. 5 (1986), 2569-2576.
- Zibert, Virology 208 (1995), 653-661.
- Zibert, Hepatology 25 (1997), 1245-1249.

Claims

AMENDED SHEET

1. An antibody comprising at least one complementarity determining region (CDR) of the V_H and/or V_L region of a human antibody comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 5 (V_L) (SEQ ID NO: 1) and Figure 6 (V_H) (SEQ ID NO: 3) that specifically recognizes a conformation-dependent epitope of Hepatitis C Virus glycoprotein E2 and is capable of precipitating covalently or non-covalently associated E2/E1 complexes.
2. The antibody of claim 1, wherein said antibody is a monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, synthetic antibody, antibody fragment, or a chemically modified derivative thereof.
3. The antibody of claim 1 or 2 comprising the amino acid sequence of the V_H and/or V_L region as depicted in SEQ ID NO: 2, 4 and/or 6.
4. An antibody recognizing the same epitope or antigen as the antibody of any one of claims 1 to 3.
5. An antigen or an epitope thereof which is recognized by the antibody of any one of claims 1 to 4.
6. A polynucleotide encoding at least a variable region of an immunoglobulin chain of the antibody of any one of claims 1 to 4.
7. A vector comprising the polynucleotide of claim 6, optionally in combination with a polynucleotide of claim 6 that encodes the variable region of the other immunoglobulin chain of said antibody.
8. A host cell comprising a polynucleotide of claim 6 or a vector of claim 7.

9. A method for preparing an antibody capable of recognizing a conformation-dependent epitope of Hepatitis C Virus glycoprotein E2 or a functional fragment or immunoglobulin chain(s) thereof comprising
- (a) culturing the cell of any one of claim 8 and
 - (b) isolating said antibody or functional fragment or immunoglobulin chain(s) thereof from the culture.
10. An antibody or fragment thereof encoded by a polynucleotide of claim 6 or obtainable by the method of claim 9.
11. A pharmaceutical composition containing a therapeutic amount of the antibody of any one of claims 1 to 4 or 10, the antigen of claim 5, the polynucleotide of claim 6, the vector of claim 7 or the cell of claim 8 and optionally a pharmaceutically acceptable carrier.
12. A diagnostic composition comprising the antibody of any one of claims 1 to 4, the antigen of claim 5, the polynucleotide of claim 6, the vector of claim 7 or the cell of claim 8 and optionally appropriate reagents conventionally used in immunodiagnostic methods.
13. A method for preventing (re)infection of Hepatitis C Virus in a subject, comprising the step of administering the antibody of any one of claims 1 to 4 or 10, the polynucleotide of claim 6 or the vector of claim 7.
14. A method for alleviating chronic Hepatitis C in a subject, comprising the step of treating said subject using the antibody of any one of claims 1 to 4 or 10 combined with a pharmaceutically acceptable carrier.
15. The method of claim 13 or 14, wherein said subject is a human or an animal.
16. A method for diagnosing chronic Hepatitis C in a subject, characterized in that samples of said subject are tested using the antibody of any one of claims 1 to

4 or 10 for the presence of neutralization of binding of Hepatitis C Virus glycoprotein E2 onto target cells.


17. A neutralization assay for inhibiting the binding of Hepatitis C Virus glycoprotein E2 onto target cells using the antibody of any one of claims 1 to 4.
18. An in vitro immunoassay for the presence of Hepatitis C Virus glycoprotein E2, characterized by measuring its co-precipitation with the antibody of any one of claims 1 to 4 or 10 under non-reducing conditions.
19. A method for detecting antibodies against Hepatitis C Virus in a subject comprising contacting a sample from a subject with the antigen of claim 5; and detecting the presence of antibodies bound to said antigen.
20. Use of the antibody of any one of claims 1 to 4 or 10, the antigen of claim 5, the polynucleotide of claim 6, the vector of claim 7 or the cell of claim 8 for the preparation of a pharmaceutical composition for the treatment or prevention of HCV infection in a subject or for the prevention of recurrence of HCV infection.
21. The use of claim 20, wherein said pharmaceutical composition is designed to be administered prior, during or after liver transplantation.

09/11/2006 14:44:50


ABSTRACT

Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

09744476-064304




A



B



C




D

Figure 1

09/744176-051304




E



F

Figure 1 continued

09/744176-064804



B)

Amino acid boundaries

340-674

340-522

A: 384-443
B: 444-503
C: 504-556
D: 557-607
E: 609-674

A B C D E

pS2.SE2-A-E

Figure 2

4/7




Figure 3




Figure 4
Concentration of HumAbs (µg/ml)

5'	TCT	TAC	⁹ GAG	CTC	ACG	¹⁸ CAG	CCG	CCC	²⁷ TCG	GTG	TCA	³⁶ GTG	TCC	CCA	⁴⁵ GGA	CAG	ACG	⁵⁴ GCC
	S	Y	E	L	T	Q	P	P	S	V	S	V	S	P	G	Q	T	A
	AGG	ATC	⁶³ ACC	TGC	TCT	⁷² GGA	GAT	GCA	⁸¹ TTG	CCA	AAG	⁹⁰ CAA	TAT	GCT	⁹⁹ TAC	TGG	TAT	¹⁰⁸ CAG
	R	I	T	C	S	G	D	A	L	P	K	Q	Y	A	Y	W	Y	Q
	CAG	AAG	¹¹⁷ CCA	GGC	CAG	¹²⁶ GCC	CCT	GTG	¹³⁵ TTG	GTG	ATA	¹⁴⁴ TAT	AAA	GAT	¹⁵³ AAT	GAG	AGG	¹⁶² CCC
	Q	K	P	G	Q	A	P	V	L	V	I	Y	K	D	N	E	R	P
	TCA	GGG	¹⁷¹ ATC	CCT	GAG	¹⁸⁰ CGA	TTC	TCT	¹⁸⁹ GGC	TCC	AGG	¹⁹⁸ TCA	GGG	ACA	²⁰⁷ ACA	GTC	ACG	²¹⁶ TTG
	S	G	I	P	E	R	F	S	G	S	R	S	G	T	T	V	T	L
	ACC	ATC	²²⁵ AGT	GGA	GTC	²³⁴ CAG	GCA	GAA	²⁴³ GAC	GAG	GCT	²⁵² GAC	TAT	TAC	²⁶¹ TGT	CAA	TCA	²⁷⁰ GCA
	T	I	S	G	V	Q	A	E	D	E	A	D	Y	Y	C	Q	S	A
	GAC	AGC	²⁷⁹ AGT	GGT	TCT	²⁸⁸ TCC	TGG	GTG	²⁹⁷ TTC	GGC	GGA	³⁰⁶ GGG	ACC	AAG	³¹⁵ CTG	ACC	GTC	³²⁴ CTA
	D	S	S	G	S	S	W	V	F	G	G	G	T	K	L	T	V	L

3'

Figure 5

5'	CAG	GTG	⁹ CAG	CTA	CAG	¹⁸ CAG	TGG	GGC	²⁷ GCA	GGA	CTG	³⁶ TTG	AAG	CCT	⁴⁵ TCG	GAG	ACC	⁵⁴ CTG
	Q	V	Q	L	Q	Q	W	G	A	G	L	L	K	P	S	E	T	L
	TCC	CTC	⁶³ ACC	TGC	GCT	⁷² GTC	TAT	GGT	⁸¹ GGG	TCC	TTA	⁹⁰ AGT	GGT	TAC	⁹⁹ TTC	TGG	ACC	¹⁰⁸ TGG
	S	L	T	C	A	V	Y	G	G	S	L	S	G	Y	F	W	T	W
	ATC	CGC	¹¹⁷ CAG	TCC	CCC	¹²⁶ GGG	AAG	GGG	¹³⁵ CTG	GAG	TGG	¹⁴⁴ ATT	GGG	GAA	¹⁵³ AGC	AAT	TAT	¹⁶² AGT
	I	R	Q	S	P	G	K	G	L	E	W	I	G	E	S	N	Y	S
	GGA	AGT	¹⁷¹ ACC	AGG	TAC	¹⁸⁰ AAC	CCG	TCC	¹⁸⁹ CTC	AAG	AGT	¹⁹⁸ CGA	GTC	ACC	²⁰⁷ ATA	TCA	GTA	²¹⁶ GAC
	G	S	T	R	Y	N	P	S	L	K	S	R	V	T	I	S	V	D
	ACG	TCC	²²⁵ CAG	AAC	CAG	²³⁴ TTC	TCC	CTG	²⁴³ AAG	CTG	AGC	²⁵² TCT	GTG	ACC	²⁶¹ GCC	GCG	GAC	²⁷⁰ ACG
	T	S	Q	N	Q	F	S	L	K	L	S	S	V	T	A	A	D	T
	GCT	GTA	²⁷⁹ TAT	TAC	TGT	²⁸⁸ GCG	AGA	GGT	²⁹⁷ TGG	GCG	GTG	³⁰⁶ GAC	GGT	ATG	³¹⁵ GAC	GTC	TGG	³²⁴ GGC
	A	V	Y	Y	C	A	R	G	W	A	V	D	G	M	D	V	W	G
	CAA	GGG	³³³ ACC	ACG	GTC	³⁴² ACC	GTC	TCC	³⁵¹ TCA	3'								
	Q	G	T	T	V	T	V	S	S									

Figure 6

DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, We hereby declare that our residences, post office addresses and citizenships are as stated below next to our names; We believe we are the original and first co-inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled, ANTI HEPATITIS C VIRUS ANTIBODY AND USES THEREOF, in the application filed in the U.S. Patent and Trademark Office on 19 January 2001 and assigned Serial No. 09/744,176.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of the instant application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

We hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any foreign application for patent or inventor's certificate, of any PCT international application designating at least one country other than the United States of America or of any provisional application listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications

Application No.	Country	Date Filed	Priority Claimed
PCT/EP99/05173	WIPO	20 July 1999	Yes
EP 98 11 3595.7	EP	21 July 1998	Yes

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(None) (Application No.)	(Filing Date)	(Status: patented, pending, abandoned)

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued therefrom.

We hereby appoint David S. Abrams, Reg. No. 22,576; Robert H. Berdo, Reg. No. 19,415; Alfred N. Goodman, Reg. No. 26,458; Mark S. Bicks, Reg. No. 28,770; John E. Holmes, Reg. No. 29,392; Lance G. Johnson, Reg. No. 32,531; Dean H. Nakamura, Reg. No. 33,981; Garrett V. Davis, Reg. No. 32,023; Joseph J. Buczynski, Reg. 35,804; and Stacey J. Longanecker, Reg. 33,952 all of ROYLANCE, ABRAMS, BERDO &

DECLARATION AND POWER OF ATTORNEY
U.S. Appln. Ser. No. 09/744,176

GOODMAN, L.L.P., WHOSE ADDRESS IS 1300 19TH STREET, SUITE 600, WASHINGTON, DC 20036,
TELEPHONE NUMBER (202) 659-9076, our attorneys and/or agents with full power of substitution and
revocation, to prosecute the instant application and to transact all business in the Patent and Trademark
Office connected therewith.

PLEASE DIRECT ALL CORRESPONDENCE AND TELEPHONE CALLS TO DEAN H.
NAKAMURA AT THE ABOVE ADDRESS AND TELEPHONE NUMBER.

1-00 Full Name of First
Inventor:

Christian Reiter

Inventor's Signature:

Christian Reiter

Date of Signature:

16 Feb 2001

Residence Address:

Rathausstrasse 8, D-85757 Karlsfeld, Germany FLX

Post Office Address:

Rathausstrasse 8, D-85757 Karlsfeld, Germany

Country of
Citizenship:

Germany

2-00 Full Name of Second
Inventor:

Francois Habersetzer

Inventor's Signature:

Francois Habersetzer

Date of Signature:

April 18, 2001

Residence Address:

2 rue de Provence, F-67400 Illkirch-Graffenstaden, France FLX

Post Office Address:

2 rue de Provence, F-67400 Illkirch-Graffenstaden, France

Country of
Citizenship:

France

3-00 Full Name of Third
Inventor:

Anne Fournillier

Inventor's Signature:

A Fournillier

Date of Signature:

April 3, 2001

Residence Address:

6 rue de Pr Sisley, F-69003 Lyon, France FLX

Post Office Address:

6 rue de Pr Sisley, F-69003 Lyon, France

Country of
Citizenship:

France

DECLARATION AND POWER OF ATTORNEY
U.S. Appln. Ser. No. 09/744,176

4th Full Name of Fourth
Inventor:

Christian Trepo

Inventor's Signature:



Date of Signature:

March 28 2001

Residence Address:

4 passage du Verdier Sud, F-69500 Bron, France FLX

Post Office Address:

4 passage du Verdier Sud, F-69500 Bron, France

Country of
Citizenship:

France

5th Full Name of Fifth
Inventor:

Claude Desgranges

Inventor's Signature:



Date of Signature:

April 30, 2001

Residence Address:

129 bis avenue de Choisy, F-75013 Paris, France FLX

Post Office Address:

129 bis avenue de Choisy, F-75013 Paris, France

Country of
Citizenship:

France

6th Full Name of Sixth
Inventor:

Genevieve Inchauspe

Inventor's Signature:



Date of Signature:

March 26 2001

Residence Address:

4 rue Villon, F-69003 Lyon, France FLX


Post Office Address:

4 rue Villon, F-69003 Lyon, France

Country of
Citizenship:

France

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. *Some drawings are too dark.*